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1. Introduction
Children with Down syndrome (DS) have a 10- to 20-fold increased risk of developing acute
leukemia. [1-4] The relative risk of developing acute megakaryoblastic leukemia (AMKL) is
estimated to be 500 times higher in children with DS than in those without DS. Interestingly,
five to 10 % of neonates with DS develop transient abnormal myelopoiesis (TAM). In most
cases, it resolves spontaneously within 3 months. However, approximately 15% of the severe
cases are fatal and 20% of patients develop AMKL until 3 year-old (Fig.1). AMKL in DS has a
number of distinct features and it is now considered a specific subtype of acute myeloid
leukemia (AML) in the 4th edition of the World Health Organization (WHO) classification
called Myeloid Leukemia of Down syndrome (ML-DS).
2. Acute Myeloid Leukemia (AML)
The majority of cases of AML with DS (70-100%) are megakaryoblastic [5] and occur within
the first 4 years of life. [6] The characteristic antecedent preleukaemic TAM is observed in 20–
30% of cases. Overt leukemia in DS children is preceded in 20- 60% of cases by an indolent
myelodysplasia, characterised by thrombocytopenia and bone marrow fibrosis, which may
last several months before overt AML. [1, 7] The median age at presentation of AML is 1.8
years. [7] The bone marrow aspirate shows dysplasia, increased blasts, abnormal megakaryo‐
cytes and variable myelofibrosis.[5, 7-8] Immunophenotypically, ML-DS blasts typically
express megakaryocytic (CD42b and CD41) and erythroid markers (CD36 and Glycophorin
A) as well as the T cell marker, CD7. [9]Neither the favorable cytogenetic changes, such as
t(8;21), t(15;17), t(9;11) and inv(16), nor the AMKL-associated translocations, t(1;22) and t(1;3),
occur in ML-DS.[1] Additional copies of chromosome 8 and/or 21 (in addition to the +21c,
10-15%), monosomy 7 and –5/5q- (together in 10–20%) are observed. [10]
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2.1. Treatment for AML-DS
Conventional treatment of AML-DS has been associated with excessive treatment-related
mortality (TRM), cardiac toxicity due to anthracyclines and serious infections. Zwaan et al
demonstrated a 12-fold increase in sensitivity to cytarabine in DS-AML cells compared with
non-DS AML cells, as well as increased sensitivity to anthracyclines (two- to seven-fold) and
etoposide (20-fold).[11] Several collaborative study groups have adapted their standard AML
protocol for AML-DS by reducing the dose of drugs (Table 1).[5, 8, 12-17] In the Children’s
Oncology Group (COG) trial A2971 (n=132), [13] etoposide, dexamethasone, and the mainte‐
nance course were eliminated from the previous CCG2891 protocol. COG A2971 achieved a
5-year EFS rate of 79% plus or minus 7% (versus 77% plus or minus 7% in the CCG2891 trial)
while maintaining a low induction failure rate of 6.4%, attaining a 0% CNS relapse rate, and
sustaining an acceptably low 5-year postremission. In the AML-BFM98 study (n=66), [7] AML-
DS patients were treated with reduced doses of anthracyclines and cytarabine compared with
the previous AMLBFM93 protocol (n = 44). The cumulative doses of anthracyclines and
cytarabine were 220 to 240mg/m2 and 23 to 29g/m2 in the BFM98 study, and 440mg/m2 and
Figure 1. Multi-step model of myeloid leukemogenesis in DS. Trisomy 21 enhances the proliferation of fetal liver meg‐
akaryo-erythroid progenitors via PDGF and/or TGF beta. The acquisition of GATA1 mutation further enhances the clo‐
nal proliferation of immature magakaryoblasts diagnosed at birth as TAM. GATA1 mutations are necessary but
insufficient for the development of AMKL. Additional genetic events such as trisomy 8, or JAK2/3 mutations have
been proposed in progression from TAM to AMKL.
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23.3 g/m2 in the AMLBFM93 study, respectively. Outcome improved significantly for patients
treated in the AMLBFM98 study, with a 3-year EFS of 91% plus or minus 4% versus 70% plus
or minus 7% in the AMLBFM93 study.
Drugs administered
Protocol No ofpatients EFS (%)
Relapse
(%)
death in
CCR (%)
Cytarabine
(g/m2)
Daunorubici
n (mg/m2)
Mitoxantron
e (mg/m2)
Etoposide
(mg/m2)
POG942112 57 77 (5y) 7 14 20.7 135 80 1,000
CCG28915 161 77 (6y) 14 4 15.8 320 0 1,600
COG-A297113 132 79 (5y) 11 3 24.8 80 0 0
NOPHO-AML9314 41 85 (8y) 7 5 49.6 150 30 1,600
AML-BFM987 67 89 (3y) 6 5 23-29 Ida; 26-36 0-14 950
MRC-AML10/128 46 74 (5y) 3 15 7.8 300 50 1,500
AT-DS(Japan)15 33 80 (8y) 6 9 4.2 100-400 0 2,700
AML99 DS16 72 83 (4y) 12.5 1.4 3.5 THP; 250 0 2,250
JCCLSG 9805DS17 24 83 (5y) 0 13 12.6 THP; 135 10 200
POG, Pediatric Oncology Group; CCG, Children's Cancer Group; COG, Children's Oncology Group; NOPHO,
Nordic Society for Paediatric Haematology and Oncology; BFM, Berlin-Frankfurt-Munster; MRC, Medical
Research Council; JCCLSG; Japan Children's Cancer and Leukemia Study Group DS, Down syndrome;
Ida, Idarubicin; THP, pirarubicin
Table 1. Comparison of the results in DS-AML patients
A treatment regimen specifically designed for AML-DS has been used in Japan since the
mid- 1980s.[15, 16] AML 99 DS protocol consisted of pirarubicin (25 mg/m2/d, on days 1
and 2),  which was estimated to be equivalent as 25mg/m2/d of  daunomycin (DNR),  cy‐
tarabine  (100  mg/m2/d  on  day  1  through  7),  and  etoposide  (150  mg/m2/d  on  day  3
through 5). Pirarubicin is much less cardiotoxic and more myelosuppressive than daunor‐
ubicin.A total of 70 of the 72 patients (97.2%) achieved a CR. The 4-year EFS was 83.3%
plus or minus 9.1% and the 4-year OS was 83.7% plus or minus 9.5%. The regimen-relat‐
ed toxicities were relatively tolerable. Only one patient died as a result of pneumonia in
the second course of intensification. The 3-year EFS in the five patients with monosomy 7
was significantly worse than in the 65 patients without monosomy 7 (40,0% plus or mi‐
nus 26.3% v 86.2% plus or minus 8.8%). Future treatment protocols could include adher‐
ence  to  a  very  low-intensity  chemotherapy  for  the  majority  of  ML-DS  patients,
identification  of  the  subgroup  with  a  poor  prognosis  using  minimal  residual  disease
(MRD), and stratification of these patients to receive a more intensive chemotherapy con‐
taining high-dose and/or continuous infusion of intermediate-dose cytarabine.
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3. Transient Abnormal Myelopoiesis (TAM)
Transient abnormal myelopoiesis (TAM), also known as transient leukemia (TL) or transient
myeloproliferative disorder (TMD) occurs in approximately 10% of infants with DS.[1, 4] TAM
was considered to be ‘‘self-limiting’’; the prognosis of TAM was favorable, except for the risk
of the subsequent development of acute leukemia. Most of newborns are asymptomatic and
only present with circulating blast cells, with or without leucocytosis. Other clinical features
include hepatomegaly, splenomegaly, serous effusions and, in up to 10% of patients, liver
fibrosis due to blast cell infiltration that can rarely cause fulminant liver failure. Leucocytosis
and thrombocytopenia are common. About a quarter of patients have abnormal liver transa‐
minases and abnormal laboratory coagulation tests. The blast cells in TAM usually have the
‘blebby’ appearance characteristic of megakaryoblasts and typically express CD41, CD42b.
Most neonates with TAM do not need chemotherapy as the clinical and laboratory abnormal‐
ities spontaneously resolve within 3–6 months after birth. However, symptomatic babies with
TAM, especially those with high blast counts or liver dysfunction, may benefit from low-dose
cytarabine.
In 2006, Children’s Oncology Group (COG) reported a prospective study of the natural history
of 48 children with DS and TAM. [18] Early death occurred in 17% of infants and was signifi‐
cantly correlated with higher WBC count at diagnosis, increased bilirubin and liver enzymes,
and failure to normalize the blood count. Recurrence of leukemia occurred in 19% of infants
at a mean of 20 months. In the AML-BFM study, 22 children among total 146 children (15%)
died within the first 6 months. The 5-year OS and EFS were 85% plus or minus 3% and 63%
plus or minus 4%, respectively. [19]A total of 28 children received a short course of cytarabine
treatment. Interestingly, EFS and OS did not differ significantly in the treated versus the
untreated group. Among the 124 children who survived the first 6 months of life, 29 (23.4%)
subsequently developed ML-DS. The 5-year EFS after diagnosis of ML-DS for all 29 patients
was 91% plus or minus 5%, which is significantly higher than the 5-year EFS of those of ML-
DS patients without documented TAM (70% plus or minus 4%). According to the retrospective
study from Japan, estimated gestational age (EGA), higher WBC counts and higher direct
bilirubin levels were significant predictive factors for poor prognosis. [20, 21] Muramatsu et
al devised a simple risk stratification system based on the EGA and the peak WBC count. The
high-risk group (HR) was defined as preterm infants with WBC >100 x 109/l, the intermediate-
risk group (IR) was defined as preterm infants with WBC <100 x 109/l and term infants with
WBC >100 x 109/l, and the low-risk group (LR) was defined as term infants with WBC< 100 x
109/l. In the LR group, only three of 39 patients (7.7 %) died early. Based on their data, patients
in the LR group should receive no interventions. However, since the probability of early death
in patients in the HR group exceeded 50%, active intervention including low dose cytarabine
should be tried in the context of a clinical trial for these patients.
3.1. Treatment for TAM
In patients with a severe form of TAM, the main causes of death in early life are progressive
hepatic fibrosis, cardiopulmonary failure, and disseminated intravascular coagulation. These
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complications may be caused by blast cell infiltration into visceral organs. In the Pediatric
Oncology Group (POG) study 9481, 10 mg/m2 per dose or 1.2–1.5 mg/kg per dose was given
subcutaneously or intravenously by slow injection twice a day for 7 days (Table 2). [18] In the
AML-BFM study, 0.5–1.5 mg/kg was administered for 3–12 days. [19] As TAM blasts are highly
sensitive to cytarabine, there is generally a rapid response, characterized by the disappearance
of peripheral blasts by day 7 of treatment.
Study group No ofpatients
Early death
(%)
Leukemia
(%)
OS
(%)
No of treated
patients Cytarabine
POG948118 48 17 19 78 (3y) 2 10mg/m2 x 2 x 1-2days
AML-BFM19 146 15 23.4* 85 (5y) 28 0.5-1.5 mg/kg x 3-12days
COGA297120 135 21 16 77 (3y) 29 3.33mg/kg/24 hrs x 5days
Tokai (Japan)21 70 23 22* 74.3(1y) 3 0.7 mg/kg x 5days,10mg/m2 x 2/day
Kikuchi (Japan)22 73 22 23 71.2(3y) 9
POG, Pediatric Oncology Group; BFM, Berlin-Frankfurt-Munster;
COG, Children’s Oncology Group; *. Alive > 6 mo
Table 2. The outcomes of transient abnormal myelopoiesis with Down syndrome.
Although TAM resolves in the majority of DS infants, 20– 30% subsequently develop ML-DS,
usually within in the first 4 years of life. [18-22] In the COG study 2971, twenty-one patients
among total 135 TAM patients (16%) developed ML-DS, including 3 received cytarabine.[20]
The development of AMKL after remission of TAM has been interested as a model of myeloid
leukaemogenesis, presumably from a subclone of persisting TMD cells that acquire a selective
advantage. This hypothesis can be verified by monitoring minimal residual disease, either by
immunophenotype or quantitative GATA1[23] polymerase chain reaction.
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